242 related articles for article (PubMed ID: 34471940)
21. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
22. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)].
Klöppel G
Pathologe; 2019 May; 40(3):211-219. PubMed ID: 30969346
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
Popa Ilie IR; Georgescu CE
Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
[TBL] [Abstract][Full Text] [Related]
24. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms.
Zhang WH; Wang WQ; Gao HL; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188311. PubMed ID: 31442475
[TBL] [Abstract][Full Text] [Related]
25. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
26. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study.
Masui T; Ito T; Komoto I; Uemoto S;
BMC Cancer; 2020 Nov; 20(1):1104. PubMed ID: 33189127
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
[TBL] [Abstract][Full Text] [Related]
28. Update on gastroenteropancreatic neuroendocrine tumors.
Andreasi V; Partelli S; Muffatti F; Manzoni MF; Capurso G; Falconi M
Dig Liver Dis; 2021 Feb; 53(2):171-182. PubMed ID: 32912771
[TBL] [Abstract][Full Text] [Related]
29. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study.
Abdel-Rahman O; Fazio N
J Neuroendocrinol; 2021 May; 33(5):e12971. PubMed ID: 33870570
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study.
Feola T; Puliani G; Sesti F; Modica R; Centello R; Minotta R; Cannavale G; Di Meglio S; Di Vito V; Lauretta R; Appetecchia M; Colao A; Lenzi A; Isidori AM; Faggiano A; Giannetta E
J Endocrinol Invest; 2022 Apr; 45(4):849-857. PubMed ID: 35040099
[TBL] [Abstract][Full Text] [Related]
32. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
Garcia-Alvarez A; Cubero JH; Capdevila J
Curr Oncol Rep; 2022 Apr; 24(4):451-461. PubMed ID: 35171460
[TBL] [Abstract][Full Text] [Related]
33. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs): The Role of Checkpoint Inhibitors.
Arrivi G; Fazio N
Curr Cancer Drug Targets; 2022 Aug; 22(8):629-638. PubMed ID: 35034595
[TBL] [Abstract][Full Text] [Related]
34. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs).
Mohamed A; Asa SL; McCormick T; Al-Shakhshir H; Dasari A; Mauricio R; Salem I; Ocuin LM; Bajor D; Lee RT; Selfridge JE; Kardan A; Lee Z; Avril N; Kopp S; Winter JM; Hardacre JM; Ammori JB; Ghannoum MA
Curr Issues Mol Biol; 2022 Apr; 44(5):2015-2028. PubMed ID: 35678665
[TBL] [Abstract][Full Text] [Related]
35. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.
Fang JM; Li J; Shi J
World J Gastroenterol; 2022 Mar; 28(10):1009-1023. PubMed ID: 35431496
[TBL] [Abstract][Full Text] [Related]
36. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Dai M; Mullins CS; Lu L; Alsfasser G; Linnebacher M
World J Gastrointest Surg; 2022 May; 14(5):383-396. PubMed ID: 35734622
[TBL] [Abstract][Full Text] [Related]
38. Spatial profiling reveals tissue-specific neuro-immune interactions in gastroenteropancreatic neuroendocrine tumors.
Duan S; Sawyer TW; Witten BL; Song H; Else T; Merchant JL
J Pathol; 2024 Mar; 262(3):362-376. PubMed ID: 38229586
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]